DOCSLIB.ORG

Beta-Thalassemia: from Genotype to Phenotype

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Beta-Thalassemia: from Genotype to Phenotype Editorials and Perspectives Beta-thalassemia: from genotype to phenotype Fabrice Danjou, Franco Anni, Renzo Galanello Dipartimento di Scienze Biomediche e Biotecnologie, Università di Cagliari, Ospedale Regionale Microcitemie ASL8, Cagliari, Italy E-mail: [email protected] doi:10.3324/haematol.2011.055962 (Related Original Article on page 1712) eta-thalassemias are heterogeneous autosomal a chain imbalance as a consequence of reduced a chain recessive hereditary anemias characterized by output. 4 Breduced or absent b globin chain synthesis. The A substantial decrease in a/non- a chain imbalance can resulting relative excess of unbound a globin chains pre - also be obtained through the coinheritance of genetic cipitate in erythroid precursors in the bone marrow, lead - determinants able to sustain a continuous production of ing to their premature death and, hence, to ineffective gamma chains which, binding the excess a chains, result erythropoiesis. b-thalassemia phenotypes are variable, in a persistent fetal hemoglobin (Hb F) production meas - ranging from the severe transfusion dependent tha - urable in adult life. In delta- b0 thalassemia, this ability is lassemia major to the mild form of thalassemia interme - due to deletions of variable extent within the b globin dia. Patients with the major form of the disease have cluster, 5 while in other cases it depends on the co-trans - severe anemia, microcytic and hypochromic anemia, mission of point mutations at A-gamma or G-gamma hepatosplenomegaly, and usually come to medical atten - promoters (−196 C →T A-gamma; −158 C →T G- tion within the first two years of life. Without treatment, gamma). 6,7 A mild phenotype may also be determined by affected children have severely compromised growth and coinheritance of genetic determinants associated with development and shortened life expectancy. Treatment increased gamma chain production mapping outside the with a regular transfusion program and chelation therapy, b globin cluster. Different polymorphisms at the BCL11A aimed at reducing transfusional iron overload, allows for gene on 2p16.1 8 and HBS1L-MYB intergenic region on normal growth and development and extends life 6q23.3 have been described. 9,10 Several polymorphisms expectancy into the third to fifth decade. 1 Individuals within intron 2 of the BCL11A gene have been strongly with thalassemia intermedia present later in life, have associated with Hb F levels: rs766432, rs4671393, milder anemia (that never or only rarely requires transfu - rs1427407 and rs11886868, all in high linkage disequilib - sion), liver and spleen enlargement, typical bone modifi - rium (LD) with each other. 11-15 Other independent signals cations, and mild to moderate jaundice. 2 Occasionally in the same area were also identified with rs10189857 patients with thalassemia intermedia are completely and rs7599488, in high LD, as well as rs7606173 and asymptomatic until adult life with only mild anemia. The rs6706648, 13 also in high LD with each other. 12,13 In the major and intermedia forms of the disease are the two HBS1L-MYB intergenic region, different SNPs have been extremes of a wide range of clinical variability. Each described as being associated with Hb F variations in dif - group includes a continuous scale of severity, as demon - ferent studies: rs9399137, as well as rs4895441, strated by the variability in age at which thalassemia rs9402686 and rs28384513. 10,12 However, evidence has major patients need transfusion; from months to years of been reported of other contributing loci that have not life. been validated in recent genome-wide association stud - Beta -thalassemias are also very heterogeneous at the ies, such as the 8q26-28 and Xp22.2–22.3 loci. 16,17 molecular level, with more than 200 disease-causing Together with these discoveries, the interest for predic - mutations so far identified; a complete updated list is tion of Hb F levels and b-thalassemia phenotype has nat - available at the Globin Gene Server Web Site - http://glo - urally grown in recent years, and the three loci previously bin.cse.psu.edu/. In most cases, mutations are single mentioned have now been reported to be responsible for nucleotide substitutions, deletions or insertions of single 20 to 50% of the Hb F trait variance in patients with b- nucleotides or small oligonucleotides leading to thalassemia or sickle cell disease, and in healthy frameshift. Their diversity and the consequent variable Europeans. 18 Meanwhile, Galanello et al. reported the degree of globin chain imbalance are the main determi - impact of variants in the BCL11A and HBS1L-MYB loci nants for milder phenotypes, the coinheritance of together with a gene defects on the clinical severity of homozygosity or compound heterozygosity for mild b- b0-39-thalassemia, quantifying their overall contribution thalassemia alleles being responsible for a consistent resid - to 75% of the variation differences between b0-39- ual output of b chains from the affected b globin locus. thalassemia major and intermedia phenotypes. 14 However, much of the phenotypic variability is also The work by Badens et al. , presented in this issue of the explained by other genetic determinants capable of reduc - Journal, extends previous studies by integrating the −158 ing the a/non- a chain imbalance thereby resulting in a C→T G-gamma polymorphism and b0/ b+ status, in addi - lesser degree of a chain precipitation. 3 tion to rs11886868 in the BCL11A gene, rs9389268 in the One of the first discovered mechanisms able to reduce HBS1L-MYB intergenic region and a globin genes this imbalance is the coinheritance with homozygous b- defects, to define b-thalassemia severity. 19 Multivariate thalassemia of a-thalassemia determinant. In this case, analysis including these five genetic modifiers was car - the severity of the clinical phenotype correlates with the ried out and an accurate prediction has been made regard - a globin chain deficiency and with the improved a/non- ing major/intermedia status in more than 80% of haematologica | 2011; 96(11) 1573 Editorials and Perspectives patients. The heterogeneity of this 106 patient cohort, Pediatric Clinic II of the Thalassemia Unit at Ospedale with thirty different b globin gene mutations, might Regionale per le Microcitemie (a WHO Collaborating Center introduce variability not accountable for in the model, but for Community Control of Hereditary Disease) and of the it certainly provides a large amount of information on the Department Biomedical Sciences and Biotechnologies, Cagliari, prediction ability of the b0/ b+ status. Also, while it is Italy. His main research interests are the clinical aspects and likely that future studies will better define the genetic molecular genetics of thalassemias and other hemoglo - polymorphisms that modulate the effect of the BCL11A binopathies, glucose-6-phosphate dehydrogenase deficiency, and HBS1L-MYB intergenic region loci and eventually and Gilbert syndrome. Over the last ten years he has been the uncover causal variants, results from Badens et al. already principal investigator of several clinical trials of new oral iron provide clinically relevant information to practitioners, chelators. He is author of over 210 peer reviewed publications clarifying the impact of genetic modifiers on the clinical and is co-author of the books “Prevention of thalassemias and severity of the disease. Furthermore, future studies will other haemoglobin disorders” (vols. 1 and 2), edited by the probably expand this predictive ability, including the Thalassemia International Federation, and of the chapter “The effect of the different strongest independent predictors Thalassemias” in Wintrobe’s Clinical Hematology book (11th known to date for each gene (or even identified causal edition). variants), and will eventually relate genetic modifiers to a more detailed measurement of clinical severity. Financial and other disclosures provided by the author using Very few other complex disease phenotypes can be the ICMJE (www.icmje.org) Uniform Format for Disclosure of explained in such depth, and prediction of patient risk as Competing Interests are available with the full text of this paper a function of their personal genetic background already at www.haematologica.org. offers support in clinical settings for b-thalassemia as opposed to most complex diseases. Extended molecular References diagnosis can be carried out in patients affected by 1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini homozygous b-thalassemia to define their genotype for MD, Del Vecchio GC, et al. Survival and complications in patients different modifiers and to better understand their pheno - with thalassemia major treated with transfusion and deferoxamine. typic modulation abilities. Before long, b-thalassemia Haematologica. 2004;89(10):1187-93. modifiers should allow us to redefine, on a genetic basis, 2. Weatherall DJ, Clegg JB. The thalassemia syndromes. 4th Ed, Blackwell Science Ltd. 2001. the phenotypic definition actually in use. 3. Cao A, Galanello R, Rosatelli MC. Genotype-phenotype correlations Linkage analysis and genome-wide association studies in beta-thalassemias. Blood Rev. 1994;8(1):1-12. have greatly contributed to such results, and next genera - 4. Galanello R, Cao A. Relationship between genotype and phenotype. Thalassemia intermedia. Ann N Y Acad Sci. 1998;850:325-33. tion sequencing might further improve prediction ability 5. Loudianos G, Cao A, Ristaldi MS, Pirastu M, Tzeti M, Kannavakis E, and eventually guide the development of new therapies. et al. Molecular basis of delta beta-thalassemia with normal fetal At present, recent studies on Hb F modifier genes have hemoglobin level. Blood. 1990;75(2):526-8. 6. Tasiopoulou M, Boussiou M, Sinopoulou K, Moraitis G, Loutradi- produced mixed results: while a 3bp deletion associated Anagnostou A, Karababa P. G gamma-196 C-->T, A gamma-201 C-- with Hb F levels has been recently identified in the >T: two novel mutations in the promoter region of the gamma-globin HBS1L-MYB intergenic region, 20 no such results have genes associated with nondeletional hereditary persistence of fetal been obtained with the sequencing of the BCL11A gene.
Load more

Recommended publications
  • Diagnosis of Sickle Cell Disease and HBB Haplotyping in the Era of Personalized Medicine: Role of Next Generation Sequencing
    Journal of Personalized Medicine Article Diagnosis of Sickle Cell Disease and HBB Haplotyping in the Era of Personalized Medicine: Role of Next Generation Sequencing Adekunle Adekile 1,*, Nagihan Akbulut-Jeradi 2, Rasha Al Khaldi 2, Maria Jinky Fernandez 2 and Jalaja Sukumaran 1 1 Department of Pediatrics, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait; jalajasukumaran@hotmail 2 Advanced Technology Company, Hawali 32060, Kuwait; [email protected] (N.A.-J.); [email protected] (R.A.); [email protected] (M.J.F.) * Correspondence: [email protected]; Tel.: +965-253-194-86 Abstract: Hemoglobin genotype and HBB haplotype are established genetic factors that modify the clinical phenotype in sickle cell disease (SCD). Current methods of establishing these two factors are cumbersome and/or prone to errors. The throughput capability of next generation sequencing (NGS) makes it ideal for simultaneous interrogation of the many genes of interest in SCD. This study was designed to confirm the diagnosis in patients with HbSS and Sβ-thalassemia, identify any ß-thal mutations and simultaneously determine the ßS HBB haplotype. Illumina Ampliseq custom DNA panel was used to genotype the DNA samples. Haplotyping was based on the alleles on five haplotype-specific SNPs. The patients studied included 159 HbSS patients and 68 Sβ-thal patients, previously diagnosed using high performance liquid chromatography (HPLC). There was Citation: Adekile, A.; considerable discordance between HPLC and NGS results, giving a false +ve rate of 20.5% with a S Akbulut-Jeradi, N.; Al Khaldi, R.; sensitivity of 79% for the identification of Sβthal.
    [Show full text]
  • PATHOLOGY RESIDENT HEMATOLOGY ROTATION (North Florida/South Georgia Veterans Health Care System): Rotation Director: William L
    PATHOLOGY RESIDENT HEMATOLOGY ROTATION (North Florida/South Georgia Veterans Health Care System): Rotation Director: William L. Clapp, M.D., Chief, Hematology Section, Gainesville VAMC; Consultants: Neil S. Harris, M.D., Director, Laboratory Hematology/Coagulation, University of Florida and Shands Hospital and Raul C. Braylan, M.D., Director, Hematopathology, University of Florida and Shands Hospital 1. Description of the Rotation: In this rotation, the resident will gain experience in laboratory hematology, which will include (1) peripheral blood studies to evaluate a variety of hematologic disorders, including anemias, lymphoproliferative and myeloproliferative disorders and leukemias. The emphasis on a multidisciplinary approach to diagnose hematologic disorders (including correlation of the peripheral blood studies with bone marrow and lymph node studies) provides an opportunity for the resident to also gain additional experience in (2) traditional histopathology, (3) immunohistochemistry, (4) electron microscopy, (5) protein electrophoresis, (6) flow cytometry, (7) cytogenetics and (8) molecular genetics which may be performed on the peripheral blood, bone marrow or lymph nodes of patients. The residents will acquire valuable experience by independently performing some bone marrow procedures. In addition, the resident will gain experience in coagulation testing. The residents will become familiar with the instrumentation in the hematology laboratory, including the operating principles and trouble-shooting (medical knowledge). The availability of assembled case study sets and reading materials (medical knowledge) will enhance the resident’s experience. Participation in CAP surveys, continuing education and hematology conferences is a component of the rotation (practice-based learning). Management issues and computer applications will be discussed (practice-based learning). As appropriate to the individual case or consultation under review, the ethical, socioeconomic, medicolegal and cost-containment issues will be reviewed and discussed.
    [Show full text]
  • Thalassemia, Hemophilia & Sickle Cell Disease
    10/22/2018 Global Best Practices in Care, Rehabilitation and Research Thalassemia Syndrome Blood Disorders (Thalassemia, Hemophilia & Sickle Cell Disease) Dr. J.S. Arora Thalassemialogist 7% of the world population MSc in Haemoglobinopathy University College London Carry Thalassemia/Hb’pathy gene General secretary: National Thalassemia Welfare Society Federation of Indian Thalassemics Member Ethics Committee: 400 million heterozygous carriers IIT Delhi Lady Hardinge Medical College and Associated Hospitals, New Delhi ITS Dental College Hospital & Research Centre, Greater NOIDA 3,00,000-4,00,000 babies with severe Founder Member: Indian Alliance of Patient Groups haemoglobinopathies born each year. Founding Trustee: Genomics And Public Health Foundation Formerly Coordinator Thalassemia Cell Govt. of Delhi Member Advisory Committee - D D U Hospital Govt. of Delhi INDIA , THAILAND AND INDONESIA “Life Time Service Award” from PHO Chambers of IAP ► 50% OF WORLD’S THALASSAEMIA CARRIERS Patients for Patient Safety (PFPS) Champion India Member: Patients for Patient Safety Advisory Group ► 50% OF THALASSAEMIA MAJORS [email protected] β Thalassemia Who are affected 100 million carriers of β Thalassemia. More than 100,000 Thalassemia Major born/year India • thalassemia : Carrier rate 1% - 17% (mean 3.9%) more prevalent in certain communities. 50 million carriers, Over 12,000 affected born every year. • Sickle Cell Disease : common in tribes carrier rate as high as 40% in some areas • HbE : Highly prevalent in West Bengal & North Eastern
    [Show full text]
  • Section 8: Hematology CHAPTER 47: ANEMIA
    Section 8: Hematology CHAPTER 47: ANEMIA Q.1. A 56-year-old man presents with symptoms of severe dyspnea on exertion and fatigue. His laboratory values are as follows: Hemoglobin 6.0 g/dL (normal: 12–15 g/dL) Hematocrit 18% (normal: 36%–46%) RBC count 2 million/L (normal: 4–5.2 million/L) Reticulocyte count 3% (normal: 0.5%–1.5%) Which of the following caused this man’s anemia? A. Decreased red cell production B. Increased red cell destruction C. Acute blood loss (hemorrhage) D. There is insufficient information to make a determination Answer: A. This man presents with anemia and an elevated reticulocyte count which seems to suggest a hemolytic process. His reticulocyte count, however, has not been corrected for the degree of anemia he displays. This can be done by calculating his corrected reticulocyte count ([3% × (18%/45%)] = 1.2%), which is less than 2 and thus suggestive of a hypoproliferative process (decreased red cell production). Q.2. A 25-year-old man with pancytopenia undergoes bone marrow aspiration and biopsy, which reveals profound hypocellularity and virtual absence of hematopoietic cells. Cytogenetic analysis of the bone marrow does not reveal any abnormalities. Despite red blood cell and platelet transfusions, his pancytopenia worsens. Histocompatibility testing of his only sister fails to reveal a match. What would be the most appropriate course of therapy? A. Antithymocyte globulin, cyclosporine, and prednisone B. Prednisone alone C. Supportive therapy with chronic blood and platelet transfusions only D. Methotrexate and prednisone E. Bone marrow transplant Answer: A. Although supportive care with transfusions is necessary for treating this patient with aplastic anemia, most cases are not self-limited.
    [Show full text]
  • Acquired Hemophilia A: Pathogenesis and Treatment
    Bleeding disorders Acquired hemophilia A: pathogenesis and treatment P.W. Collins ABSTRACT Arthur Bloom Haemophilia Centre, Acquired hemophilia A is an autoimmune disease caused by an inhibitory antibody to factor VIII. The School of Medicine, severity of bleeding varies but patients remain at risk of life-threatening bleeding until the inhibitor Cardiff University, Heath Park, has been eradicated. The cornerstones of management are rapid and accurate diagnosis, control of Cardiff, UK bleeding, investigation for an underlying cause, and eradication of the inhibitor by immunosuppres - sion. Patients should be managed jointly with a specialist center even if they present without signifi - cant bleeding. Despite an extensive literature, few controlled data are available and management Hematology Education: guidelines are based on expert opinion. Recombinant factor VIIa and activated prothrombin complex the education program for the concentrate are equally efficacious for treating bleeds and both are superior to factor VIII or desmo - annual congress of the European pressin. Immunosuppression should be started as soon as the diagnosis is made. Commonly used reg - Hematology Association imens are steroids alone or combined with cytotoxic agents. Rituximab is being used more commonly but current evidence does not suggest that it improves outcomes or reduces side effects. 2012;6:65-72 Introduction Pathogenesis Acquired hemophilia A (AHA) is a bleed - AHA is associated with autoimmune dis - ing disorder caused by polyclonal IgG1 and eases, such as rheumatoid arthritis, polymyal - IgG4 autoantibodies to the factor VIII ( FVIII ) gia rheumatic, and systemic lupus erythe - A2 and C2 domain. Morbidity and mortality matosis; malignancy; pregnancy and dermato - are high secondary to age, underlying dis - logical disorders, such as pemphigoid.
    [Show full text]
  • Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant
    Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease 1 Produced by St. Jude Children’s Research Hospital Departments of Hematology, Patient Education, and Biomedical Communications. Funds were provided by St. Jude Children’s Research Hospital, ALSAC, and a grant from the Plough Foundation. This document is not intended to take the place of the care and attention of your personal physician. Our goal is to promote active participation in your care and treatment by providing information and education. Questions about individual health concerns or specifi c treatment options should be discussed with your physician. For more general information on sickle cell disease, please visit our Web site at www.stjude.org/sicklecell. Copyright © 2009 St. Jude Children’s Research Hospital How did bone marrow (stem cell) transplants begin for children with sickle cell disease? Bone marrow (stem cell) transplants have been used for the treatment and cure of a variety of cancers, immune system diseases, and blood diseases for many years. Doctors in the United States and other countries have developed studies to treat children who have severe sickle cell disease with bone marrow (stem cell) transplants. How does a bone marrow (stem cell) transplant work? 2 In a person with sickle cell disease, the bone marrow produces red blood cells that contain hemoglobin S. This leads to the complications of sickle cell disease. • To prepare for a bone marrow (stem cell) transplant, strong medicines, called chemotherapy, are used to weaken or destroy the patient’s own bone marrow, stem cells, and infection fi ghting system.
    [Show full text]
  • Haemophilia a Is the Most Common Form – Affecting
    Haemophilia is an inherited, serious It can dramatically reduce bleeding disorder where a person’s the quality of life of people blood does not clot properly, leading affected, as well as their family, to uncontrolled bleeding which can friends and caregivers1. occur spontaneously or after minor trauma. Haemophilia A is the most common form – affecting 50-60% of whom have severe haemophilia4. blood of a person In a healthy person, proteins called clotting factors work together to form a blood clot and help stop bleeding. People with haemophilia A either lack or do not have enough of a clotting factor called which leads to their blood not being able to clot properly. Bruising Repeated bleeding into muscles and joints, which can lead to long term disability or joint disease5 Spontaneous bleeding, which can be life threatening if it occurs in vital organs, such as the brain Prolonged and uncontrolled bleeding following injury or surgery6,7 Life for people with haemophilia and their caregivers is often centred on treatment infusions, taking up a large amount of time and having a significant impact on their lives8. People with haemophilia A report difficulty balancing treatment with daily life, so compliance can be a challenge9,10 leaving them vulnerable to potentially dangerous bleeds. The mainstay of current treatment for haemophilia A is factor VIII replacement therapy, which is taken on-demand (as needed to treat bleeds), or on an ongoing basis (to prevent bleeds). It is short-acting and so needs to be administered frequently (at least twice a week)2 by the patient or a caregiver and for some, especially children, finding a vein for medicine infusion can be difficult11.
    [Show full text]
  • Outcomes of Patients with Thrombocytopenia Evaluated at Hematology Subspecialty Clinics
    Henry Ford Health System Henry Ford Health System Scholarly Commons Hematology Oncology Articles Hematology-Oncology 2-11-2021 Outcomes of patients with thrombocytopenia evaluated at hematology subspecialty clinics Zaid H. Abdel Rahman Kevin C. Miller H Jabbour Yaser Alkhatib Vijayalakshmi Donthireddy Follow this and additional works at: https://scholarlycommons.henryford.com/ hematologyoncology_articles Hematol Oncol Stem Cell Ther xxx (xxxx) xxx Available at www.sciencedirect.com ScienceDirect journal homepage: www.elsevier.com/locate/hemonc Outcomes of patients with thrombocytopenia evaluated at hematology subspecialty clinics Zaid H. Abdel Rahman a,*, Kevin C. Miller b, Hiba Jabbour c, Yaser Alkhatib c, Vijaya Donthireddy c a Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA b Department of Medicine, Massachusetts General Hospital, Boston, MA, USA c Division of Hematology and Medical Oncology, Henry Ford Hospital, Detroit, MI, USA Received 6 October 2020; received in revised form 9 December 2020; accepted 15 January 2021 KEYWORDS Abstract Hematology; Background: Thrombocytopenia is a frequently encountered laboratory abnormality and a Malignancy; common reason for hematology referrals. Workup for thrombocytopenia is not standardized Platelets; and frequently does not follow an evidence-based algorithm. We conducted a systematic anal- Referrals; Thrombocytopenia ysis to evaluate the laboratory testing and outcomes of patients evaluated for thrombocytope- nia at hematology clinics in a tertiary referral center between 2013 and 2016. Patient and methods: We performed a comprehensive chart review for patients evaluated for thrombocytopenia during the study period. Patients were followed for 1 year from the initial hematology evaluation and assessed for the development of a hematologic malignancy, rheumatologic, or infectious diseases among other clinical outcomes.
    [Show full text]
  • Download Download
    Acta Biomed 2021; Vol. 92, N. 1: e2021169 DOI: 10.23750/abm.v92i1.11345 © Mattioli 1885 Update of adolescent medicine (Editor: Vincenzo De Sanctis) Rare anemias in adolescents Joan-Lluis Vives Corrons, Elena Krishnevskaya Red Blood Cell Pathology and Hematopoietic Disorders (Rare Anaemias Unit) Institute for Leukaemia Research Josep Car- reras (IJC). Badalona (Barcelona) Abstract. Anemia can be the consequence of a single disease or an expression of external factors mainly nutritional deficiencies. Genetic issues are important in the primary care of adolescents because a genetic diagnosis may not be made until adolescence, when the teenager presents with the first signs or symptoms of the condition. This situation is relatively frequent for rare anemias (RA) an important, and relatively heteroge- neous group of rare diseases (RD) where anaemia is the first and most relevant clinical manifestation. RA are characterised by their low prevalence (< 5 cases per 10,000 individuals), and, in some cases, by their complex mechanism. For these reasons, RA are little known, even among health professionals, and patients tend to re- main undiagnosed or misdiagnosed for long periods of time, making impossible to know the prognosis of the disease, or to carry out genetic counselling for future pregnancies. Since this situation is an important cause of anxiety for both adolescent patients and their families, the physician’s knowledge of the natural history of a genetic disease will be the key factor for the anticipatory guidance for diagnosis and clinical follow-up. RA can be due to three primary causes: 1. Bone marrow erythropoietic defects, 2. Excessive destruction of mature red blood cells (hemolysis), and 3.
    [Show full text]
  • Alpha Thalassemia Trait
    Alpha Thalassemia Trait Alpha Thalassemia Trait Produced by St. Jude Children’s Research Hospital, Departments of Hematology, Patient Education, 1 and Biomedical Communications. Funds were provided by St. Jude Children’s Research Hospital, ALSAC, and a grant from the Plough Foundation. This document is not intended to replace counseling by a trained health care professional or genetic counselor. Our aim is to promote active participation in your care and treatment by providing information and education. Questions about individual health concerns or specific treatment options should be discussed with your doctor. For general information on sickle cell disease and other blood disorders, please visit our Web site at www.stjude.org/sicklecell. Copyright © 2009 St. Jude Children’s Research Hospital Alpha thalassemia trait All red blood cells contain hemoglobin (HEE muh glow bin), which carries oxygen from your lungs to all parts of your body. Alpha thalassemia (thal uh SEE mee uh) trait is a condition that affects the amount of hemo- globin in the red blood cells. • Adult hemoglobin (hemoglobin A) is made of alpha and beta globins. • Normally, people have 4 genes for alpha globin with 2 genes on each chromosome (aa/aa). People with alpha thalassemia trait only have 2 genes for alpha globin, so their bodies make slightly less hemoglobin than normal. This trait was passed on from their parents, like hair color or eye color. A trait is different from a disease 2 Alpha thalassemia trait is not a disease. Normally, a trait will not make you sick. Parents who have alpha thalassemia trait can pass it on to their children.
    [Show full text]
  • Hematology/Oncology
    Hematology/Oncology Description: The pediatric hematology-oncology division sees a wide spectrum of pediatric disease including but not limited to leukemia, hemophilia, solid tumors, ITP, and other blood dyscrasias. The pediatric resident is expected to be involved in the work-up and on-going management of all patient presenting to the hem-onc service. Note: The goals and objectives described in detail below are not meant to be completed in a single one month block rotation but are meant to be cumulative, culminating in a thorough and complete Pediatric Hem-Onc experience at the end of residency. Primary Goals for this Rotation GOAL: Prevention, Counseling and Screening. Understand the role of the pediatrician in preventing hematologic or oncologic conditions, and in counseling and screening individuals at risk for these diseases. Provide routine preventive counseling about hematology to all patients and families, addressing: 1. Adequate diet and iron intake to prevent iron deficiency 2. Signs and symptoms of malignant disease Provide preventive counseling to parents and patients with specific hematology/oncology conditions, addressing: 1. In a child with a sickle hemoglobinopathy, the importance of antibiotic prophylaxis, pneumococcal and routine immunizations, folic acid supplementation, and urgent need for evaluation for fever 2. Risk of infections related to transfusion of blood or blood products, and alternatives to routine transfusion (i.e., direct donation, irradiation, freezing, filtration) 3. Expected course of common childhood malignancies, with good and bad prognosticators 4. Support groups and information available for children with cancer Provide regular hematology/oncology screening for patients: 1. Screen for hemoglobinopathies in the newborn period.
    [Show full text]
  • The Voice of the Patient: Sickle Cell Report
    The Voice of the Patient A series of reports from the U.S. Food and Drug Administration’s (FDA’s) Patient-Focused Drug Development Initiative Sickle Cell Disease Public Meeting: February 7, 2014 Report Date: October 2014 Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) U.S. Food and Drug Administration (FDA) Table of Contents Introduction ......................................................................................................................................3 Meeting overview ..................................................................................................................................... 3 Report overview and key themes ............................................................................................................. 4 Topic 1: The Effects of Sickle Cell Disease That Matter Most to Patients ..............................................6 Pediatric and young adult perspective on the effects of sickle cell disease ............................................. 6 Adult perspective on the effects of sickle cell disease ........................................................................... 10 Topic 2: Patient Perspectives on Treatments for Sickle Cell Disease and Participation in Clinical Trials 12 Sickle cell disease treatments ................................................................................................................. 13 Non-drug therapies ................................................................................................................................
    [Show full text]